- Active Substance: IGF-1 LR3
- Concentration: 1 mg
- Pack Size: vial
- Manufacturer: Ultima Pharmaceuticals
- Brand Name: DES 1-3
SKU: P282
Shipping From
Understanding Ultima-DES (1-3) 1mg (IGF-1 LR3) for Localized Muscle Growth Research
Ultima-DES (1-3), offered by Ultima Pharmaceuticals, contains 1mg per vial of Insulin-like Growth Factor 1 Long Arg3 (IGF-1 LR3), often referred to in research as a modified or truncated form of IGF-1. While the name "DES (1-3)" might suggest a specific fragment, in the context of the active substance being IGF-1 LR3, it indicates a research peptide being investigated for its potential to promote localized muscle growth and repair.
Mechanism of Action
IGF-1 LR3 is a synthetic analog of human Insulin-like Growth Factor 1 (IGF-1). The "Long Arg3" modification makes it more potent and longer-acting than native IGF-1 by reducing its binding to IGF-1 binding proteins. Research focuses on its potential to stimulate muscle hypertrophy (growth) by activating signaling pathways involved in protein synthesis and cell proliferation. The term "DES (1-3)" sometimes refers to a specific truncated form of IGF-1 that lacks the first three amino acids, which is also studied for its anabolic effects, particularly when administered locally.
Benefits
- Investigated for its potential to promote localized muscle growth when administered directly into muscle tissue.
- Studied for its effects on accelerating muscle repair and recovery from exercise-induced damage.
- Research into its potential to enhance satellite cell activation and differentiation, crucial for muscle regeneration.
- Exploration of its role in increasing nutrient uptake and utilization in muscle cells.
Please note: The potential benefits listed above are based on preclinical and some limited clinical research and have not been fully established in humans for widespread therapeutic use. IGF-1 LR3 and related peptides are research compounds and are not approved for human therapeutic use by regulatory authorities in many regions.
Usage Guidelines
As a research compound, any guidelines regarding its use are strictly within the context of laboratory and research settings. Administration protocols and dosages vary significantly depending on the specific research objectives and models. Research often involves localized intramuscular injection. Any information regarding human dosage or administration is speculative and not recommended.
Potential Side Effects
Research on IGF-1 LR3 and related peptides has indicated potential side effects such as hypoglycemia (low blood sugar), especially at higher systemic doses, and localized injection site reactions. The long-term safety profile and the full range of potential side effects are still under investigation.
FAQ
What is Ultima-DES (1-3) (IGF-1 LR3)?
Ultima-DES (1-3) contains IGF-1 LR3, a modified form of Insulin-like Growth Factor 1 being researched for its potential to promote localized muscle growth and repair.
How does IGF-1 LR3 work in research for muscle growth?
Research suggests it stimulates muscle hypertrophy by activating pathways involved in protein synthesis and cell proliferation.
What are the potential research benefits of IGF-1 LR3?
Potential research benefits include localized muscle growth, accelerated muscle repair, and enhanced satellite cell activity.
What are the potential side effects observed in research?
Potential side effects reported in research include hypoglycemia and localized injection site reactions.
Important Note: Ultima-DES (1-3) (IGF-1 LR3) is a research compound and is not approved for human therapeutic use by regulatory authorities in many regions. Information provided here is strictly for research and informational purposes only. It is not intended as a guide for personal use. The use of such compounds carries potential risks, and their long-term effects are not fully understood. Consult with qualified healthcare professionals for any health concerns.